EDITAS MEDICINE, INC. Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions
EDITAS MEDICINE, INC. (EDIT) reported Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions of $1.42 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions · last filed 2026-03-09
- EDITAS MEDICINE, INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2025 was $1.42M, a 29.70% decline from fiscal 2024.
- EDITAS MEDICINE, INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2024 was $2.02M, a 45.95% increase from fiscal 2023.
- EDITAS MEDICINE, INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2023 was $1.38M, a 18.97% decline from fiscal 2022.
- EDITAS MEDICINE, INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2022 was $1.71M.
| Period end | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 12 month |
|---|---|
| 2025-12-31 | $1.42M 10-K · filed 2026-03-09 |
| 2024-12-31 | $2.02M 10-K · filed 2026-03-09 |
| 2023-12-31 | $1.38M 10-K · filed 2024-02-28 |
| 2022-12-31 | $1.71M 10-K · filed 2023-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |